However, this trend did not reach statistical significance after PS matching, which was adjusted for discrepancies in person-years attributable to the relatively recent introduction of SGLT2i compared to other oral hypoglycemic agents (OHA).
← all excerpts
SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea.
1
—
—